Pharmaceuticals

NT PHARMA

NT PHARMA released FY2025 Q3 earnings on March 31, 2026 (BJT), with actual revenue of HKD 6.648 M and EPS of HKD -0.0073

NT PHARMA released FY2025 9 Months Earnings on March 31 (BJT), actual revenue HKD 19.64 M, actual EPS HKD -0.0401

NT PHARMA released FY2025 Annual Earnings on March 31 During-Market BJT, Actual Revenue HKD 26.4 M, Actual EPS HKD -0.0461

NT PHARMA released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 6.763 M, actual EPS HKD -0.0075

NT PHARMA to Release FY2025 Earnings Report on March 31 During-Market BJT

NT PHARMA released FY2025 Q1 earnings on August 8 (BJT), actual revenue HKD 6.423 M, actual EPS HKD -0.0162

Tailem Pharma Reports Increased Mid-Year Loss

NT PHARMA released FY2025 Semi-Annual earnings on August 8 During-Market (BJT), actual revenue HKD 12.99 M, actual EPS HKD -0.0327

NT PHARMA released FY2025 Q2 earnings on August 8 During-Market (BJT), actual revenue HKD 6.564 M, actual EPS HKD -0.0165

NT PHARMA to Release FY2025 Semi-Annual Earnings on August 8, 2025 (BJT)

Tailem Pharma Cooperates with State-Owned Enterprise to Launch Smart Healthcare Center

Wang Minzhi reduced holdings in Teeling Pharmaceutical

TaiLing Pharmaceutical Delays Issue of Financial Report Circular

Tailem Pharmaceutical Replaces Nomination Committee Chair and Member

China Telomycin Pharmaceutical Annual General Meeting Successfully Held

Taikang Pharma Shareholders Deposit Shares with HSBC, Kangchen Pharma Plans to Dissolve Joint Venture

Weekly Healthcare Sector Investment and Financing Totaled Approximately 360 Million Yuan

Tailem Pharma Aims to Acquire Medical Device Company Shares

Talentech China Announces Acquisition of Target Company's 100% Shares

U.S. President Trump Announces Major Tariffs on Drug Imports, Hong Kong Pharmaceutical Stocks Decline Collectively

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

01011

513700

512290

510660

159929

159992

520690

520880

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

Tip Ranks

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal 800 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

China NT Pharma Group announced that judicial records involving director Ng Tit are related to a settled loan dispute from a former subsidiary, Jiangsu Tailing Investment. The RMB119 million loan issue, linked to real estate, has been resolved without material impact on the company's operations or Ng's directorship. The company clarified that the records pertain to corporate guarantees, not personal misconduct.

CM BANK

China Merchants Bank

China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen

China NT Pharma Group Co., Ltd. has announced the structure of its board of directors, which includes executive, non-executive, and independent non-executive members, led by chairman Mr. Ng Tit. The company also detailed its three key board committees: audit, remuneration, and nomination, with leadership concentrated among independent non-executive directors to enhance governance and oversight. The company, listed in Hong Kong under stock code 1011, focuses on drug-related products and services in the Greater China market.

China NT Pharma details board and committee structure

China NT Pharma Group Co., Ltd. has scheduled its annual general meeting for June 4, 2026, in Hong Kong. The agenda includes reviewing financial statements, re-electing directors, and appointing auditors. Shareholders will also vote on granting a mandate to issue up to 20% of existing share capital, enhancing the company's financial flexibility for capital raising and corporate transactions. The company operates in the healthcare sector and is listed on the Hong Kong Stock Exchange under stock code 1011, with a current market cap of HK$635.8M.

China NT Pharma Calls 2026 AGM, Seeks Renewal of Share Issuance Mandate

159837

588130

NT PHARMA announced its 2025 annual performance, with revenue of RMB 24.158 million, a year-on-year decrease of 36.4%. The loss narrowed from RMB 53.357 million in the same period of 2024 to RMB 26.041 million; the loss per share is 4.22 cents. No final dividend is declared

AASTOCKS

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

"Performance" NT PHARMA's annual loss narrowed to 26.041 million RMB, no dividend distribution

NT PHARMA issued a profit warning, expecting a net loss of between RMB 25 million and RMB 30 million for the fiscal year 2025, compared to a loss of RMB 53.4 million recorded in the previous year, a decrease of 43.8%-53.2%. The expected reduction in loss is mainly due to the recognition of a one-time non-cash fair value loss in the previous year and a fair value gain of RMB 14 million recorded in financial assets for this year

"Profit Warning" NT PHARMA reduces loss forecast, with a maximum loss of 30 million RMB last year

NT PHARMA announced that, after further discussions between the company and Hangzhou Jingwei Life Science Technology and Huang Jianshan (the subscriber), and to ensure full compliance with listing rules, all parties have entered into a termination agreement regarding the issuance of convertible bonds with a principal amount of 65 million yuan. The company's shares have applied to resume trading on Wednesday (the 11th)

"Resumption" NT PHARMA terminates the issuance of RMB 65 million convertible bonds

China NT Pharma Group Co., Ltd. has halted trading of its shares on the Hong Kong Stock Exchange as of February 10, 2026, pending details on its convertible bond issuance. The company is preparing to provide supplemental information regarding this plan, which could impact its capital structure and financing strategy. Analysts currently rate the stock as a Hold with a price target of HK$0.76. The company focuses on healthcare and drug product development for the Chinese market and has a market cap of HK$532.7M.

E Fund Hang Seng SCHK Innovative Drug ETF

China NT Pharma Halts Trading Pending Details on Convertible Bond Issue

NT PHARMA(01011.HK)